Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Tuesday! Adam Feuerstein,